MA33302B1 - 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale - Google Patents

2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale

Info

Publication number
MA33302B1
MA33302B1 MA34394A MA34394A MA33302B1 MA 33302 B1 MA33302 B1 MA 33302B1 MA 34394 A MA34394 A MA 34394A MA 34394 A MA34394 A MA 34394A MA 33302 B1 MA33302 B1 MA 33302B1
Authority
MA
Morocco
Prior art keywords
excessive
treatment
cell proliferation
abnormal cell
diseases characterized
Prior art date
Application number
MA34394A
Other languages
Arabic (ar)
English (en)
Inventor
Ioannis Sapountzis
Heinz Stadtmueller
Daniel Kuhn
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33302B1 publication Critical patent/MA33302B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR DES COMPOSÉS DE FORMULE GÉNÉRALE (1), DANS LAQUELLE A, B, R1 À R5, RX M, N ET P SONT TELS QUE DÉFINIS DANS LA REVENDICATION 1, QUI SONT APPROPRIÉS POUR LE TRAITEMENT DE MALADIES CARACTÉRISÉES PAR UNE PROLIFÉRATION CELLULAIRE EXCESSIVE OU ANORMALE. L'INVENTION PORTE ÉGALEMENT SUR DES PRÉPARATIONS PHARMACEUTIQUES QUI CONTIENNENT DE TELS COMPOSÉS ET SUR LEUR UTILISATION EN TANT QUE MÉDICAMENTS.
MA34394A 2009-05-29 2010-05-28 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale MA33302B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09161496 2009-05-29
EP10161628 2010-04-30
PCT/EP2010/057408 WO2010136559A1 (fr) 2009-05-29 2010-05-28 2, 4-diaminopyrimidines pour le traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale

Publications (1)

Publication Number Publication Date
MA33302B1 true MA33302B1 (fr) 2012-05-02

Family

ID=42289495

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34394A MA33302B1 (fr) 2009-05-29 2010-05-28 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale

Country Status (22)

Country Link
US (1) US8410126B2 (fr)
EP (1) EP2435411B1 (fr)
JP (1) JP5756799B2 (fr)
KR (1) KR20120135010A (fr)
CN (1) CN102448943A (fr)
AP (1) AP2011005978A0 (fr)
AR (1) AR076620A1 (fr)
AU (1) AU2010251943A1 (fr)
BR (1) BRPI1014994A2 (fr)
CA (1) CA2763700A1 (fr)
CL (1) CL2011003022A1 (fr)
CO (1) CO6470899A2 (fr)
EA (1) EA201101674A1 (fr)
EC (1) ECSP11011558A (fr)
IL (1) IL216084A0 (fr)
MA (1) MA33302B1 (fr)
MX (1) MX2011012643A (fr)
PE (1) PE20120370A1 (fr)
SG (1) SG176599A1 (fr)
TW (1) TW201107308A (fr)
UY (1) UY32673A (fr)
WO (1) WO2010136559A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2054392A2 (fr) * 2006-06-15 2009-05-06 Boehringer Ingelheim International GmbH 2-anilino-4-(hétérocyclique)amino-pyrimidines comme inhibiteurs de proteine kinase c-alpha
EP2300013B1 (fr) 2008-05-21 2017-09-06 Ariad Pharmaceuticals, Inc. Dérivés phosphorés servant d'inhibiteurs de kinase
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
AU2012216893B2 (en) 2011-02-17 2016-08-11 Cancer Therapeutics Crc Pty Limited FAK inhibitors
CA2827172C (fr) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Inhibiteurs selectifs de fak
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US10710983B2 (en) * 2016-06-27 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
WO2019190259A1 (fr) * 2018-03-30 2019-10-03 한미약품 주식회사 Nouveau dérivé de sulfonamide ayant un effet inhibiteur sur la mutation du récepteur du facteur de croissance épidermique
EP3966207B1 (fr) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phénylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
CN117203199A (zh) * 2021-04-02 2023-12-08 毕利吉生物科技股份有限公司 N2-苯基嘧啶-2,4-二胺化合物及其制备方法和使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408727A1 (fr) * 2000-05-22 2001-11-29 Leo Pharma A/S Benzophenones comme inhibiteurs de l'il-1.beta. et tnf-.alpha.
WO2003030909A1 (fr) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
CA2463989C (fr) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives pyrimidine, compositions pharmaceutiques contenant ces composes, utilisation et procede de fabrication de ces composes
US7449456B2 (en) * 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL379330A1 (pl) * 2002-12-20 2006-08-21 Pfizer Products Inc. Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek
CN102127058A (zh) * 2004-05-14 2011-07-20 辉瑞产品有限公司 治疗异常细胞生长的嘧啶衍生物
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
ATE497496T1 (de) * 2006-10-19 2011-02-15 Rigel Pharmaceuticals Inc 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
US8138339B2 (en) * 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2323993B1 (fr) * 2008-04-16 2015-06-03 Portola Pharmaceuticals, Inc. 2,6-diamino- pyrimidin- 5-yl-carboxamides comme inhibiteurs de la syk ou jak protéine kinase

Also Published As

Publication number Publication date
CO6470899A2 (es) 2012-06-29
AU2010251943A1 (en) 2011-12-01
IL216084A0 (en) 2012-01-31
TW201107308A (en) 2011-03-01
AR076620A1 (es) 2011-06-22
AP2011005978A0 (en) 2011-12-31
MX2011012643A (es) 2011-12-14
US20110130401A1 (en) 2011-06-02
BRPI1014994A2 (pt) 2016-05-03
CA2763700A1 (fr) 2010-12-02
EA201101674A1 (ru) 2012-06-29
EP2435411B1 (fr) 2014-10-29
PE20120370A1 (es) 2012-05-09
SG176599A1 (en) 2012-01-30
UY32673A (es) 2010-12-31
US8410126B2 (en) 2013-04-02
WO2010136559A1 (fr) 2010-12-02
KR20120135010A (ko) 2012-12-12
JP2012528121A (ja) 2012-11-12
CN102448943A (zh) 2012-05-09
ECSP11011558A (es) 2012-01-31
CL2011003022A1 (es) 2012-07-13
JP5756799B2 (ja) 2015-07-29
EP2435411A1 (fr) 2012-04-04

Similar Documents

Publication Publication Date Title
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
TN2009000551A1 (fr) Nouveaux composes chimiques
MA32506B1 (fr) Nouveaux composes
MA50240A (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA34308B1 (fr) Triazolopyridines substituées
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
MA34474B1 (fr) Agonistes de gpr40
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
TW200612926A (en) Compounds and compositions as ppar modulators
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA30514B1 (fr) Nouveaux composes.
MA37990B1 (fr) Benzamides
MA33218B1 (fr) Applications therapeutiques de derives de quinazolinedione
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA29723B1 (fr) Composes
MA35895B1 (fr) Inhibiteurs d'iap